↓ Skip to main content

Impact of the COVID-19 Pandemic on the Diagnosis of Tuberculosis in Brazil: Is the WHO End TB Strategy at Risk?

Overview of attention for article published in Frontiers in Pharmacology, June 2022
Altmetric Badge

About this Attention Score

  • Above-average Attention Score compared to outputs of the same age and source (53rd percentile)

Mentioned by

twitter
2 X users

Readers on

mendeley
38 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Impact of the COVID-19 Pandemic on the Diagnosis of Tuberculosis in Brazil: Is the WHO End TB Strategy at Risk?
Published in
Frontiers in Pharmacology, June 2022
DOI 10.3389/fphar.2022.891711
Pubmed ID
Authors

Mariana do Rosário Souza, Wandklebson Silva da Paz, Vinícius Barbosa dos Santos Sales, Gleidson Felipe Hilario de Jesus, Débora dos Santos Tavares, Shirley V. M. Almeida Lima, Álvaro Francisco Lopes Sousa, Enaldo Vieira de Melo, Rodrigo Feliciano do Carmo, Carlos Dornels Freire de Souza, Márcio Bezerra-Santos

X Demographics

X Demographics

The data shown below were collected from the profiles of 2 X users who shared this research output. Click here to find out more about how the information was compiled.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 38 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 38 100%

Demographic breakdown

Readers by professional status Count As %
Student > Bachelor 5 13%
Student > Master 4 11%
Researcher 3 8%
Other 2 5%
Lecturer 2 5%
Other 5 13%
Unknown 17 45%
Readers by discipline Count As %
Medicine and Dentistry 5 13%
Veterinary Science and Veterinary Medicine 2 5%
Environmental Science 2 5%
Biochemistry, Genetics and Molecular Biology 2 5%
Agricultural and Biological Sciences 2 5%
Other 6 16%
Unknown 19 50%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 29 June 2022.
All research outputs
#17,727,479
of 22,764,165 outputs
Outputs from Frontiers in Pharmacology
#7,019
of 16,010 outputs
Outputs of similar age
#288,447
of 437,571 outputs
Outputs of similar age from Frontiers in Pharmacology
#495
of 1,227 outputs
Altmetric has tracked 22,764,165 research outputs across all sources so far. This one is in the 19th percentile – i.e., 19% of other outputs scored the same or lower than it.
So far Altmetric has tracked 16,010 research outputs from this source. They receive a mean Attention Score of 4.9. This one is in the 48th percentile – i.e., 48% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 437,571 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 29th percentile – i.e., 29% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 1,227 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 53% of its contemporaries.